William Blair Forecasts Ikena Oncology FY2029 Earnings

Key Points

• William Blair predicts Ikena Oncology will report an estimated fiscal year 2029 earnings per share (EPS) of ($5.41), significantly lower than the current consensus estimate of ($0.91).
• Wedbush has downgraded Ikena Oncology's price target from $25.00 to $23.00 and issued a "neutral" rating for the stock.
• Insider transactions indicate strong confidence, with Director David P. Bonita purchasing 83,611 shares and Director Otello Stampacchia buying 267,556 shares, both at an average price of $29.90 per share.

Ikena Oncology, Inc. (NASDAQ:IMA - Free Report) - Analysts at William Blair issued their FY2029 earnings estimates for shares of Ikena Oncology in a note issued to investors on Wednesday, July 30th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($5.41) for the year. The consensus estimate for Ikena Oncology's current full-year earnings is ($0.91) per share.

Ikena Oncology (NASDAQ:IMA - Get Free Report) last released its earnings results on Thursday, July 24th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.08.

Separately, Wedbush reduced their price objective on shares of Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating for the company in a research report on Friday, July 25th.

Ikena Oncology Price Performance

IMA stock traded down $0.62 during midday trading on Friday, reaching $17.28. 11,207 shares of the company were exchanged, compared to its average volume of 45,097. The business has a 50-day moving average price of $15.97 and a two-hundred day moving average price of $15.79. Ikena Oncology has a one year low of $11.65 and a one year high of $23.28. The firm has a market capitalization of $69.47 million, a price-to-earnings ratio of -2.25 and a beta of 0.51.

Insiders Place Their Bets

In related news, Director David P. Bonita acquired 83,611 shares of Ikena Oncology stock in a transaction on Friday, July 25th. The stock was purchased at an average cost of $29.90 per share, with a total value of $2,499,968.90. Following the completion of the transaction, the director directly owned 287,885 shares in the company, valued at $8,607,761.50. This trade represents a 40.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Otello Stampacchia acquired 267,556 shares of Ikena Oncology stock in a transaction on Friday, July 25th. The shares were bought at an average cost of $29.90 per share, with a total value of $7,999,924.40. Following the completion of the transaction, the director owned 454,982 shares of the company's stock, valued at approximately $13,603,961.80. This trade represents a 142.75% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 5.94% of the company's stock.

Institutional Investors Weigh In On Ikena Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of IMA. JPMorgan Chase & Co. raised its stake in Ikena Oncology by 18,244.1% in the fourth quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock valued at $255,000 after purchasing an additional 154,892 shares in the last quarter. Geode Capital Management LLC raised its stake in Ikena Oncology by 21.0% in the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after purchasing an additional 56,936 shares in the last quarter. Gilead Sciences Inc. acquired a new position in Ikena Oncology in the fourth quarter valued at about $3,294,000. Northern Trust Corp raised its stake in Ikena Oncology by 19.7% in the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in Ikena Oncology in the fourth quarter valued at about $72,000. Institutional investors and hedge funds own 75.00% of the company's stock.

About Ikena Oncology

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.